|
|
|
|
| LEADER |
02366nam a2200337 u 4500 |
| 001 |
EB001897160 |
| 003 |
EBX01000000000000001060165 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200523 r ||| eng |
| 100 |
1 |
|
|a MacDonald, Erika
|
| 245 |
0 |
0 |
|a The use of medical cannabis with other medications
|h Elektronische Ressource
|b a review of safety and guidelines - an update
|c authors, Erika MacDonald, Alison Adams
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2019, September 27, 2019
|
| 300 |
|
|
|a 1 PDF file (14 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Medical Marijuana / therapeutic use
|
| 653 |
|
|
|a Drug Interactions
|
| 653 |
|
|
|a Risk Management
|
| 653 |
|
|
|a Drug-Related Side Effects and Adverse Reactions
|
| 700 |
1 |
|
|a Adams, Alison
|e [author]
|
| 700 |
1 |
|
|a Tran, Khai
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 500 |
|
|
|a Replacement of The use of medical cannabis with other medications : a review of safety and guidelines / Khai Tran, Carolyn Spry. April 19, 2017
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK549545
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The aim of this report is to review the evidence surrounding safety of medical cannabis in combination with other medications, and relevant evidence-based guidelines. This is an update of a previous report published in April 2017, which found a single systematic review, and no evidence-based guidelines. Evidence of limited quality from two studies of oral cannabidiol in combination with other antiepileptic drugs indicated that cannabidiol may increase serum levels of clobazam. One of these two studies also found that oral cannabidiol may increase serum levels of eslicarbazepine, topiramate, zonisamide, and rufinamide. This evidence was limited by a high risk of bias and may not be generalizable to the Canadian context. Additionally, only antiepileptic drugs were studied. No evidence-based guidelines surrounding drug interactions with medical cannabis were found
|